Comprehensive Overview of CAR-T Cell Therapy, Engineering Process and Future Prospects
Bibliographic record
Abstract
Chimeric antigen receptor (CAR)-T cell therapy is a revolutionary treatment method which applies the technology of modifying patients’ immune T cells to eliminate cancer cells. The immune system recognizes invading cells by noticing antigens on the foreign cells. The receptors of T cells bind to the antigens which notifies the rest of the immune system to eradicate the foreign invaders. CAR-T cell therapy has gained achievement in the treatment of hematologic malignancies such as B-ALL. CAR-T cell engineering process contains four steps including leukapheresis and the expression of the CAR on the T cells. Among the process, the Sleeping Beauty transposon system shortens the time between genetic modification and infusion so that patients can receive the modified T cells on site. GMP (Good Manufacture Practice) also ensures quality and safety of the CAR-T cells before infusing into the patients. CAR-T cells damage tumor cells by three major pathways. T cells utilize perforin and granzyme to lyse open antigen-positive tumor cells and use Fas and Fas ligand to target antigen-negative tumor cells. The derivation of cytokines from CAR-T cells sensitizes the tumor stroma and enhances tumor killing ability. The development in CAR-T cell designs has made a huge contribution to the success of the treatment where five generations of CAR-T cells have already been investigated. However, there are still some challenges associated with the treatment such as antigen escape relapse and on-target off-tumor toxicities observed in solid tumors. The technology can be further innovated by overcoming antigen escape loss, enhancing safety of CAR-T cells, and improving the persistence of CAR-T cells using the combination of oncolytic viruses with CAR-T cells. This review mainly focuses on the CAR-T cell engineering process and killing mechanisms as well as some obstacles and potential improvement for the technology.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.001 | 0.000 |
| Meta-epidemiology (narrow) | 0.001 | 0.000 |
| Meta-epidemiology (broad) | 0.001 | 0.001 |
| Bibliometrics | 0.002 | 0.002 |
| Science and technology studies | 0.000 | 0.000 |
| Scholarly communication | 0.001 | 0.002 |
| Open science | 0.001 | 0.001 |
| Research integrity | 0.001 | 0.002 |
| Insufficient payload (model declined to judge) | 0.005 | 0.003 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".